Table III.
Cox multivariate analysis of PFS and clinical characteristics among 72 patients with advanced non-small cell lung cancer carrying EGFR mutation.
| Clinical characteristics | Exp (B) | 95%CI | P-value |
|---|---|---|---|
| Sex | 0.009 | ||
| Male vs. female | 4.600 | 1.455–14.546 | |
| Age (years) | 0.468 | ||
| <70 vs. ≥70 | 1.378 | 0.579–3.280 | |
| Histological type | <0.001 | ||
| Adenocacinoma vs. squamous | 0.011 | 0.001–0.119 | |
| Clinical stage | 0.340 | ||
| IIIB vs. IV | 0.653 | 0.272–1.567 | |
| PS score | 0.748 | ||
| 0 or 1 vs. 2 | 0.849 | 0.314–2.297 | |
| Smoking history | 0.004 | ||
| Smoker vs. non-smoker | 9.742 | 2.026–46.672 | |
| EGFR-TKI | 0.789 | ||
| Gefitinib vs. erlotinib | 0.887 | 0.368–2.136 | |
| Group | 0.046 | ||
| Exon 19 deletions vs. an exon 21 mutation | 2.256 | 1.013–5.025 |
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; PS, performance status; PFS, progression-free survival; CI, confidence interval; Exp (B), exponentiation of the B coefficient, an odds ratio.